Morning Research: Ariad Pharma Inc., MannKind Corp., Novavax Inc., and Galena
LONDON, November 1, 2013
LONDON, November 1, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Thursday, October 31, 2013, all three indexes of the US equity market edged
lower. The S&P 500 ended the day at 1,756.55, down 0.38%; the Dow Jones
Industrial Average closed at 15,545.75, down 0.47%; and the NASDAQ Composite
finished at 3,919.71, down 0.28%. Shares in the biotechnology industry mostly
ended on a lower note, tracking losses in the broader market. The major movers
in the industry included Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), MannKind
Corp. (NASDAQ: MNKD), Novavax Inc. (NASDAQ: NVAX), and Galena Biopharma Inc.
(NASDAQ: GALE). AAAResearchReports.com has released full comprehensive
research on ARIA, MNKD, NVAX, and GALE. These free technical analyses can be
downloaded by signing up at:
Ariad Pharmaceuticals Inc.'s stock plummeted on Thursday, tracking losses in
broader market. The company's shares closed the day at$2.20, down 44.44%,
after oscillating between$2.15 and $2.59 during the trading session. A total
of 64.97 million shares were traded, which is significantly above the daily
average volume of 9.08 million. The company's shares have lost 46.47% in the
previous three trading sessions, compared to a loss of 0.32% in the S&P 500
during the same period. Furthermore, Ariad Pharmaceuticals Inc.'s stock is
trading below its 50-day and 200-day moving averages of $14.59 and $17.85,
respectively. Download free report on ARIA upon registration at:
On Thursday, MannKind Corp.'s stock ended the day at $4.91, which is 0.30%
lower than the previous day's closing price of $4.92. The company's shares
fluctuated between $4.77 and $5.11 during the trading session. A total of 5.93
million shares were traded, which is below the daily average volume of 7.28
million. The company's shares have declined 6.39% in the previous trading
sessions, underperforming the S&P 500, which has lost 0.32% during the same
period. Moreover, MannKind Corp.'s stock is trading below its 50-day and
200-day moving averages of $5.61 and $5.11, respectively. MNKD technical
report can be accessed for free by signing up at:
Novavax Inc.'s stock fluctuated between gains and losses before finishing the
day flat on Thursday. The company's shares ended the session atthe previous
day's closing price of $3.10, after fluctuating between$2.96 and$3.16 during
the trading session. A total of 8.64 million shares were traded, which is
above the daily average volume of 3.04 million. The company's shares have
gained 8.98% in the previous three trading sessions and 15.06% in the last
three months, compared to a loss of 0.32% and a gain of 4.20% in the S&P 500
during the respective periods. Additionally, Novavax Inc.'s stock is trading
above its 200-day moving average of $2.41. The free report on NVAX can be
downloaded by signing up now at:
Galena Biopharma Inc.'s stock advanced 2.06% on Thursday, reversing all the
losses from the previous trading session. The company's shares oscillated
between $2.15 and $2.26 before closing the day at $2.23. A total of 1.68
million shares were traded, which is below the daily average volume of 2.58
million. The company's shares have gained 2.06% in the last three trading
sessions and 14.10% in the previous three months, outperforming the S&P 500,
which has lost 0.32% and has gained 4.20% during the respective periods.
Further, Galena Biopharma Inc.'s stock is trading above its 50-day and 200-day
moving averages of $2.18 and $2.12, respectively. A free report on GALE can be
accessed by registering at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.